- Home
- MYNZ vs IMRN Comparison
MYNZ vs IMRN Comparison
Compare MYNZ & IMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYNZ
- IMRN
- Stock Information
- Founded
- MYNZ 2021
- IMRN 1994
- Country
- MYNZ Germany
- IMRN Australia
- Employees
- MYNZ N/A
- IMRN N/A
- Industry
- MYNZ Biotechnology: Pharmaceutical Preparations
- IMRN Biotechnology: Pharmaceutical Preparations
- Sector
- MYNZ Health Care
- IMRN Health Care
- Exchange
- MYNZ Nasdaq
- IMRN Nasdaq
- Market Cap
- MYNZ 7.9M
- IMRN 9.2M
- IPO Year
- MYNZ 2021
- IMRN N/A
- Fundamental
- Price
- MYNZ $1.77
- IMRN $1.81
- Analyst Decision
- MYNZ Buy
- IMRN Strong Buy
- Analyst Count
- MYNZ 2
- IMRN 1
- Target Price
- MYNZ $14.00
- IMRN $5.00
- AVG Volume (30 Days)
- MYNZ 180.5K
- IMRN 82.1K
- Earning Date
- MYNZ 08-26-2025
- IMRN 09-08-2025
- Dividend Yield
- MYNZ N/A
- IMRN N/A
- EPS Growth
- MYNZ N/A
- IMRN N/A
- EPS
- MYNZ N/A
- IMRN N/A
- Revenue
- MYNZ $893,991.00
- IMRN $4,048,286.00
- Revenue This Year
- MYNZ $26.06
- IMRN N/A
- Revenue Next Year
- MYNZ $4.97
- IMRN N/A
- P/E Ratio
- MYNZ N/A
- IMRN N/A
- Revenue Growth
- MYNZ N/A
- IMRN 82.90
- 52 Week Low
- MYNZ $1.30
- IMRN $1.50
- 52 Week High
- MYNZ $18.40
- IMRN $2.87
- Technical
- Relative Strength Index (RSI)
- MYNZ 53.56
- IMRN 58.51
- Support Level
- MYNZ $1.41
- IMRN $1.62
- Resistance Level
- MYNZ $1.76
- IMRN $1.84
- Average True Range (ATR)
- MYNZ 0.16
- IMRN 0.09
- MACD
- MYNZ 0.02
- IMRN 0.02
- Stochastic Oscillator
- MYNZ 68.12
- IMRN 89.55
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.
About IMRN Immuron Limited
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.